Cargando…
Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders
Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atheros...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545607/ https://www.ncbi.nlm.nih.gov/pubmed/34722061 http://dx.doi.org/10.7759/cureus.18284 |
_version_ | 1784590035365920768 |
---|---|
author | El Khoury, Michel Karam, Boutros Tabet, Rabih Lafferty, James C Snyder, Stavros Thomas |
author_facet | El Khoury, Michel Karam, Boutros Tabet, Rabih Lafferty, James C Snyder, Stavros Thomas |
author_sort | El Khoury, Michel |
collection | PubMed |
description | Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity. |
format | Online Article Text |
id | pubmed-8545607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-85456072021-10-28 Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders El Khoury, Michel Karam, Boutros Tabet, Rabih Lafferty, James C Snyder, Stavros Thomas Cureus Cardiology Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity. Cureus 2021-09-25 /pmc/articles/PMC8545607/ /pubmed/34722061 http://dx.doi.org/10.7759/cureus.18284 Text en Copyright © 2021, El Khoury et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology El Khoury, Michel Karam, Boutros Tabet, Rabih Lafferty, James C Snyder, Stavros Thomas Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title | Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title_full | Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title_fullStr | Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title_full_unstemmed | Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title_short | Current Practice of Percutaneous Coronary Intervention in Patients With Coagulation Disorders |
title_sort | current practice of percutaneous coronary intervention in patients with coagulation disorders |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545607/ https://www.ncbi.nlm.nih.gov/pubmed/34722061 http://dx.doi.org/10.7759/cureus.18284 |
work_keys_str_mv | AT elkhourymichel currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders AT karamboutros currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders AT tabetrabih currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders AT laffertyjamesc currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders AT snyderstavrosthomas currentpracticeofpercutaneouscoronaryinterventioninpatientswithcoagulationdisorders |